<p>Brivudine is a thymidine analogue antiviral agent used in the treatment of herpes zoster; however, human data regarding its use during pregnancy are lacking. This report aims to describe pregnancy outcomes following oral brivudine exposure and to provide the first human clinical data on brivudine use during pregnancy. Two pregnant women exposed to oral brivudine during the first and second trimesters were referred for teratological risk assessment and followed with perinatal monitoring and postnatal clinical follow-up. Both pregnancies were continued with perinatological follow-up and resulted in the delivery of healthy infants without major congenital malformations. Postnatal follow-up identified mild allergic manifestations in one child and an isolated mild delay in the personal–social developmental domain in the other. These cases provide preliminary clinical data on brivudine exposure during pregnancy and contribute to the limited human data available.</p>